



VITEK® 2

RESULTS YOU CAN TRUST

Microbiology with Confidence

PIONEERING DIAGNOSTICS

FOCUS ON WHAT MATTERS

Designed for VITEK® 2 automated systems, VITEK Antimicrobial Susceptibility Testing (AST) panels provide reliable and accurate results for clinically important bacteria and yeasts.

RESULTS YOU CAN TRUST

The VITEK® 2 ADVANCED EXPERT SYSTEM™ (AES) software lets you focus your time where it is most required in the lab. The AES determines the consistency level of every result and quickly identifies those results truly needing a microbiologist's valuable time and attention per your laboratory's customized settings.

WE ARE FOR LEVERAGING LAB EXPERTISE

When you invest in bringing our instrumentation into your lab, you'll be supported by a team of more than 300 award winning application, engineering and customer service experts. Our VILINK® solution provides rapid access to remote diagnostic support. 24 hours a day, 365 days a year, we're ready to help you keep your lab running smoothly.



RELIABLE, ACCURATE, FLEXIBLE

PROVEN ACCURACY

- Each self-contained, disposable test panel provides accurate species-level identification or susceptibility results with Minimum Inhibitory Concentrations (MIC)

INNOVATIVE AND FLEXIBLE DESIGN:

- Each panel contains microwells with biochemicals for identification and antimicrobials for susceptibility
- Ready and simple to use
- Pre-applied barcodes for maximum traceability

STRAIGHT FORWARD PREPARATION:

- Inoculation with a simple, standardized suspension of organism in saline

Susceptibility Panels for Gram-positive Coccii

(Enterococcus spp., Staphylococcus spp., and S. agalactiae)

Antibiotic	Drug Code	MIC Calling Range	GP67	GP72	GP75	GP78	FDA Indications for Use
Ampicillin							
Enterococcus spp.	am01n	2 - 32					Enterococcus spp.
S. agalactiae	am01n	0.25 - 16					S. agalactiae
Ampicillin/Sulbactam	sam01n	2/1 - 32/16					Staphylococcus spp.
Benzylpenicillin							
Enterococcus spp.	p05n	0.12 - 64					Enterococcus spp.
Staphylococcus spp.	p05n	0.03 - 0.5					Staphylococcus spp.
S. agalactiae	p05n	0.12 - 64					S. agalactiae
Cefoxitin Screen	oxsf01n	NEG - POS					Staphylococcus spp.
Ceftaroline	ctr02n	0.06 - 4					MRSA, MSSA
Chloramphenicol	c03n	4 - 64					Enterococcus spp., Staphylococcus spp., S. agalactiae
Ciprofloxacin	cip01n	0.5 - 8					Enterococcus spp., Staphylococcus spp.
Clindamycin	cm01n	0.25 - 8					Staphylococcus spp., S. agalactiae
Clindamycin	cm04n	0.125 - 4					MSSA, MSSE
Daptomycin	dap02n	0.12 - 8					S. aureus, Vancomycin Susceptible E. faecalis
Doxycycline	do01n	0.5 - 16					S. aureus
Erythromycin	e02n	0.25 - 8					Enterococcus spp., Staphylococcus spp., S. agalactiae
Gentamicin	gm01n	0.5 - 16					Staphylococcus spp.
Gentamicin High Level (synergy)	hlg01n	S - R					Enterococcus spp.
Inducible Clindamycin Resistance	icr02n	NEG - POS					Staphylococcus spp.
Levofloxacin	lev01n	0.12 - 8					Enterococcus spp., Staphylococcus spp., S. agalactiae
Linezolid	lnz02n	0.5 - 8					E. faecium, E. faecalis, S. agalactiae, S. aureus, S. epidermidis, S. haemolyticus
Minocycline	mno01n	0.5 - 16					Enterococcus spp., Staphylococcus spp.
Moxifloxacin	mxr02n	0.25 - 8					MSSA
Nitrofurantoin	ft01n	16 - 512					Enterococcus spp., Staphylococcus spp.
Oxacillin	oxl01n	0.25 - 4					Staphylococcus spp.
Quinupristin/Dalfopristin	qda01n	0.25 - 16					MSSA, S. agalactiae, S. epidermidis, Vancomycin Resistant E. faecium
Rifampicin	ra01n	0.5 - 32					Staphylococcus spp.
Streptomycin High Level (synergy)	hls01n	S - R					Enterococcus spp.
Tetracycline	te03n	1 - 16					Enterococcus spp., Staphylococcus spp., S. agalactiae
Tigecycline	tgc02n	0.12 - 2					E. casseliflavus, E. faecalis, E. faecium, S. agalactiae, S. aureus, S. epidermidis, S. haemolyticus
Trimethoprim/Sulfamethoxazole	sxt04n	10 (0.5/9.5) 320 (16/304)					S. aureus
Vancomycin	va04n	0.5 - 32					Enterococcus spp., Staphylococcus spp., S. agalactiae

MSSA = Methicillin-susceptible *S. aureus*, MRSA = Methicillin-resistant *S. aureus*, MSSE = Methicillin-susceptible *S. epidermidis*

Expansive ID/AST Test Menu

IDENTIFICATION PANEL TYPES:

- GN (Gram-negative bacilli)
->160 organisms
- GP (Gram-positive cocci & bacilli)
->120 organisms
- ANC (Anaerobes & Corynebacteria)
->100 organisms
- NH (*Neisseria & Haemophilus*)
->30 organisms
- YST (Yeast)
->50 organisms includes *C. auris*

SUSCEPTIBILITY PANEL TYPES‡:

- Gram-negative bacilli
->30 antimicrobials and extended spectrum beta lactamase test
- Staphylococci and Enterococci
->20 antimicrobials including Cefoxitin Screen, Gentamicin High Level (Synergy), Inducible Clindamycin Resistance and Streptomycin High Level (Synergy)
- Streptococci
13 antimicrobials including Inducible Clindamycin Resistance
- Yeast
5 antimicrobials

Susceptibility Panels for Gram-negative Bacilli

Consult product package insert for FDA indications for use

Class	Antibiotic	Drug Code	MIC Calling Range	GN66 413398	GN67 413399	GN69 413400	GN70 413401	GN72 413403	GN73 413404	GN74 413391	GN77 413343	GN79 413346	GN80 413438	GN81 413437	GN83 413440	GN84 413410	GN93 414985	GN95 421982	GN99 423102	N800† 423310	N801 423416	N802 423706	XN09* 423425	XN15* 423829
Aminopenicillin & inhibitor combination	Ampicillin	am01n	2 - 32																					
	Ampicillin / Sulbactam	sam01n	2/1 - 32/16																					
	Amoxicillin / Clavulanic Acid	armc01n	2/1 - 32/16																					
Ureidopenicillin / inhibitor combinations	Piperacilllin / Tazobactam	tz03n	4/4 - 128/4																					
	Ticarcilllin / Clavulanic Acid	tcc01n	8/2 - 128/2																					
β-lactam / inhibitor combinations	Ceftazidime/Avibactam	cza02n	0.12 - 16																					
	Ceftolozane/Tazobactam	ct01n	0.25 - 32																					
	Meropenem/Vaborbactam	mrv01n	0.5 - 64																					
Cephalosporin I	Cefalotin	cf01n	2 - 64																					
	Cefazolin	cz01n	4 - 64																					
Cephalosporin II / Cephemycin	Cefotetan	ctt01n	4 - 64																					
	Cefoxitin	fox01n	4 - 64																					
	Cefuroxime	cxm01n	1 - 64																					
Cephalosporin III / IV	Cefotaxime	ctx01n	1 - 64																					
	Cefotaxime (reformulated)	ctx02n	0.25 - 64																					
	Cefpodoxime	cpd01n	0.25 - 8																					
	Ceftazidime	caz01n	1 - 64																					
	Ceftriaxone	cro01n	1 - 64																					
	Ceftriaxone (reformulated)	cro02n	0.25 - 64																					
	Cefepime	fep02n	1 - 64																					
Monobactam	Cefepime (reformulated)	fep03n	0.12 - 32																					
	Aztreonam	atm01n	1 - 64																					
ESBL	ESBL Confirmation Test	esb01n	+/-																					
	Ertapenem	etp01n	0.5 - 8																					
Carbapenem	Ertapenem (reformulated)	etp02n	0.12 - 8																					
	Imipenem	ipm04n	0.25 - 16																					
	Imipenem (reformulated)	ipm05n	0.25 - 16																					
	Meropenem	mem02n	0.25 - 16																					
Aminoglycoside	Amikacin	an01n	2 - 64																					
	Amikacin (reformulated)	an03n	1 - 64																					
	Gentamicin	gm01n	1 - 16																					
	Gentamicin (reformulated)	gm02n	1 - 16																					
	Tobramycin	tm01n	1 - 16																					
	Tobramycin (reformulated)	tm02n	1 - 16																					
Fluoroquinolone	Ciprofloxacin	cip01n	0.25 - 4																					
	Ciprofloxacin (reformulated)	cip02n	0.06 - 4																					
	Levofloxacin	lev02n	0.12 - 8																					
	Moxifloxacin	mxf01n	0.25 - 8																					
Tetracyclines	Doxycycline	do01n	0.5 - 16																					
	Minocycline	mmo02n	0.5 - 32																					
	Tetracycline	te01n	1 - 16																					
	Tigecycline	tgc01n	0.5 - 8																					
	Tigecycline (reformulated)	tgc02n	0.5 - 8																					
Miscellaneous	Nalidixic Acid	na01n	2 - 32																					
	Nitrofurantoin	ft01n	16 - 512																					
	Trimethoprim / Sulfamethoxazole	sxt02n	20 (1/19) - 320 (16/304)																					

*mates to GN69 & GN95 †mates to N802 ‡Note: Deduce ceftriaxone based on cefotaxime

AST-ST02 420915 Streptococcus Susceptibility Panel

Antimicrobial	Drug Code	MIC Calling Range	FDA Indications for Use
Ampicillin	am01n	0.25 - 16	grpBetaHS, grpVIR
Benzylpenicillin	p01n	0.06 - 8	grpC/G, <i>S. pyogenes</i> , <i>S. agalactiae</i> , <i>S. pneumoniae</i> , grpVIR
Cefotaxime	ctx01n	0.12 - 8	<i>S. pneumoniae</i> , SpyA, <i>Streptococcus</i> spp.
Ceftriaxone	cro01n	0.12 - 8	grpVIR, <i>S. agalactiae</i> , <i>S. pneumoniae</i> , <i>S. pyogenes</i>
Clindamycin	cm01n	0.25 - 1	SP(Pen(S)), <i>S. pyogenes</i> , <i>S. agalactiae</i> , <i>S. mitis</i> , <i>S. oralis</i>
Erythromycin	e01n	0.12 - 8	<i>S. pneumoniae</i> , <i>S. pyogenes</i> , grpVIR
Inducible Clindamycin Resistance	icr01n	NEG - POS	<i>S. agalactiae</i> , <i>S. pyogenes</i>
Levofloxacin	lev01n	0.25 - 16	SP+MDRSP, <i>S. pyogenes</i> , grpC/F, grpG, <i>S. agalactiae</i> , grpVIR, <i>S. milleri</i>
Linezolid	lnz01n	2 - 8	SP+MDRSP, <i>S. agalactiae</i> , <i>S. pyogenes</i>
Moxifloxacin	mxf01n	0.06 - 4	<i>S. anginosus</i> , <i>S. constellatus</i> , SP+MDRSP, <i>S. pyogenes</i> , <i>S. agalactiae</i> , grpVIR
Tetracyclines	te01n	0.25 - 16	<i>S. pneumoniae</i> , <i>S. pyogenes</i> , grpVIR
Tigecycline	tgc01n	0.06 - 1	SP(Pen(S)), <i>S. anginosus</i> grp. (includes <i>S. anginosus</i> , <i>S. intermedius</i> , and <i>S. constellatus</i>), <i>S. agalactiae</i> , <i>S. pyogenes</i>
Trimethoprim/ Sulfamethoxazole	sxt01n	10 (0.5/9.5) 320 (16/304)	<i>S. pneumoniae</i> .
Vancomycin	va01n	0.12 - 8	grpVIR, <i>S. pyogenes</i> , <i>S. agalactiae</i>

grpBetaHS = Beta-hemolytic group Streptococcus species, grpVIR = Viridans group Streptococcus, grpC/G = Beta-hemolytic Streptococcus groups C and G, SpyA = *S. pyogenes* (Group A beta-hemolytic streptococci), SP(Pen(S)) = *S. pneumoniae* (penicillin-susceptible strains) SP+MDRSP = *S. pneumoniae* (including multi-drug resistant strains (MDRSP)) grpC/F = Beta-hemolytic Streptococcus groups C and F grpG = Beta-hemolytic Streptococcus group G.

AST-YS09 423331 Antifungal Susceptibility Panel

Antifungal	Drug Code	MIC Calling Range	FDA Indications for Use
Caspofungin	cas02n	0.125 - 8	<i>C. albicans</i> , <i>C. glabrata</i> , <i>C. guilliermondii</i> , <i>C. krusei</i> , <i>C. parapsilosis</i> , <i>C. tropicalis</i>
Fluconazole	flu02n	0.5 - 64	<i>C. albicans</i> , <i>C. dubliniensis</i> , <i>C. guilliermondii</i> , <i>C. lusitaniae</i> , <i>C. parapsilosis</i> , <i>C. tropicalis</i>
Flucytosine	fct02n	1 - 64	<i>C. albicans</i> , <i>C. dubliniensis</i> , <i>C. glabrata</i> , <i>C. guilliermondii</i> , <i>C. lusitaniae</i> , <i>C. parapsilosis</i> , <i>C. tropicalis</i>
Micafungin	mcf02n	0.06 - 8	<i>C. albicans</i> , <i>C. glabrata</i> , <i>C. guilliermondii</i> , <i>C. krusei</i> , <i>C. parapsilosis</i> , <i>C. tropicalis</i>
Voriconazole (SDD)	vrc01n	0.12 - 8	<i>C. albicans</i> , <i>C. guilliermondii</i> , <i>C. lusitaniae</i> , <i>C. krusei</i> , <i>C. parapsilosis</i> , <i>C. tropicalis</i>

SDD = Susceptible-Dose Dependent (SDD) reports as Intermediate (I).

Order reagents and track shipments:

www.biomerieuxDIRECT.com

For more information, contact your local bioMérieux representative.

Customer Service: (800) 682-2666 • www.biomerieux-usa.com/vitek